Top Searches
Advertisement

Novartis India’s Q4 Miracle: Net Profit Soars 99%, Margins Hit Five-Quarter High


Updated: May 12, 2025 09:50

Image Source: CNBC TV18
Novartis India has delivered a stellar performance for the March 2025 quarter, with its standalone net profit surging by an impressive 99.59% year-on-year to ₹29.3 crore, up from ₹14.68 crore in the same period last year. The pharmaceutical giant’s robust results come on the back of improved operational efficiency and a strong uptick in non-operating income, marking its highest profit in five quarters.
 
Key Highlights:
  • Profit Surge: Net profit for Q4 FY25 soared 99.59% to ₹29.3 crore, delivering the highest quarterly profit in over a year. Earnings per share (EPS) also hit a five-quarter high at ₹11.87, reflecting enhanced shareholder value.
  • Revenue Growth: Sales for the quarter rose moderately by 3.34% to ₹83.88 crore, compared to ₹81.17 crore in Q4 FY24, indicating steady business momentum despite a challenging market environment.
  • Operating Performance: Operating profit margin (OPM) jumped to 28.51% from 13.81% a year ago, showcasing significant operational improvements and cost management.
  • Non-Operating Income: The quarter saw a notable rise in non-operating income, which reached ₹10.63 crore-the highest in five quarters. While this boosted overall profitability, analysts are watching for the sustainability of such income streams in future quarters.
  • Annual Performance: For the full year ended March 2025, Novartis India’s net profit rose 18.44% to ₹100.9 crore, with annual sales up 6.33% to ₹356.27 crore.
  • Market Reaction: The strong results have positioned Novartis India as a standout performer in the pharma sector this earnings season, with analysts highlighting both the operational turnaround and the need to monitor future income mix.
Sources: Business Standard, CNBC TV18, MarketsMojo, Capital Market

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement